Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies

A literature-based meta-analysis

Bruno Vincenzi, Massimo Di Maio, Marianna Silletta, Loretta D'Onofrio, Chiara Spoto, Maria Carmela Piccirillo, Gennaro Daniele, Francesca Comito, Eliana Maci, Giuseppe Bronte, Antonio Russo, Daniele Santini, Francesco Perrone, Giuseppe Tonini

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Background The European Association for the Study of the Liver (EASL) criteria and the modified Response Evaluation Criteria in Solid Tumors (mRECIST) are currently adopted to evaluate radiological response in patients affected by HCC and treated with loco-regional procedures. Several studies explored the validity of these measurements in predicting survival but definitive data are still lacking. Aim To conduct a systematic review of studies exploring mRECIST and EASL criteria usefulness in predictive radiological response in HCC undergoing loco-regional therapies and their validity in predicting survival. Methods A comprehensive search of the literature was performed in electronic databases EMBASE, MEDLINE, COCHRANE LIBRARY, ASCO conferences and EASL conferences up to June 10, 2014. Our overall search strategy included terms for HCC, mRECIST, and EASL. Locoregional procedures included transarterial embolization (TAE), transarterial chemoembolization (TACE) and cryoablation. Inter-method agreement between EASL and mRECIST was assessed using the k coefficient. For each criteria, overall survival was described in responders vs. non-responders patients, considering all target lesions response. Results Among 18 initially found publications, 7 reports including 1357 patients were considered eligible. All studies were published as full-text articles. Proportion of responders according to mRECIST and EASL criteria was 62.4% and 61.3%, respectively. In the pooled population, 1286 agreements were observed between the two methods (kappa statistics 0.928, 95% confidence interval 0.912-0.944). HR for overall survival (responders versus non responders) according to mRECIST and EASL was 0.39 (95% confidence interval 0.26-0.61, p

Original languageEnglish
Article numbere0133488
JournalPLoS One
Volume10
Issue number7
DOIs
Publication statusPublished - Jul 31 2015

Fingerprint

hepatoma
meta-analysis
Liver
Meta-Analysis
Tumors
Hepatocellular Carcinoma
therapeutics
liver
neoplasms
Survival
confidence interval
Therapeutics
Confidence Intervals
Cryosurgery
systematic review
MEDLINE
lesions (animal)
Libraries
electronics
Publications

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies : A literature-based meta-analysis. / Vincenzi, Bruno; Di Maio, Massimo; Silletta, Marianna; D'Onofrio, Loretta; Spoto, Chiara; Piccirillo, Maria Carmela; Daniele, Gennaro; Comito, Francesca; Maci, Eliana; Bronte, Giuseppe; Russo, Antonio; Santini, Daniele; Perrone, Francesco; Tonini, Giuseppe.

In: PLoS One, Vol. 10, No. 7, e0133488, 31.07.2015.

Research output: Contribution to journalArticle

Vincenzi, Bruno ; Di Maio, Massimo ; Silletta, Marianna ; D'Onofrio, Loretta ; Spoto, Chiara ; Piccirillo, Maria Carmela ; Daniele, Gennaro ; Comito, Francesca ; Maci, Eliana ; Bronte, Giuseppe ; Russo, Antonio ; Santini, Daniele ; Perrone, Francesco ; Tonini, Giuseppe. / Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies : A literature-based meta-analysis. In: PLoS One. 2015 ; Vol. 10, No. 7.
@article{289ec453d7be407ab8a403ef24cd281e,
title = "Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: A literature-based meta-analysis",
abstract = "Background The European Association for the Study of the Liver (EASL) criteria and the modified Response Evaluation Criteria in Solid Tumors (mRECIST) are currently adopted to evaluate radiological response in patients affected by HCC and treated with loco-regional procedures. Several studies explored the validity of these measurements in predicting survival but definitive data are still lacking. Aim To conduct a systematic review of studies exploring mRECIST and EASL criteria usefulness in predictive radiological response in HCC undergoing loco-regional therapies and their validity in predicting survival. Methods A comprehensive search of the literature was performed in electronic databases EMBASE, MEDLINE, COCHRANE LIBRARY, ASCO conferences and EASL conferences up to June 10, 2014. Our overall search strategy included terms for HCC, mRECIST, and EASL. Locoregional procedures included transarterial embolization (TAE), transarterial chemoembolization (TACE) and cryoablation. Inter-method agreement between EASL and mRECIST was assessed using the k coefficient. For each criteria, overall survival was described in responders vs. non-responders patients, considering all target lesions response. Results Among 18 initially found publications, 7 reports including 1357 patients were considered eligible. All studies were published as full-text articles. Proportion of responders according to mRECIST and EASL criteria was 62.4{\%} and 61.3{\%}, respectively. In the pooled population, 1286 agreements were observed between the two methods (kappa statistics 0.928, 95{\%} confidence interval 0.912-0.944). HR for overall survival (responders versus non responders) according to mRECIST and EASL was 0.39 (95{\%} confidence interval 0.26-0.61, p",
author = "Bruno Vincenzi and {Di Maio}, Massimo and Marianna Silletta and Loretta D'Onofrio and Chiara Spoto and Piccirillo, {Maria Carmela} and Gennaro Daniele and Francesca Comito and Eliana Maci and Giuseppe Bronte and Antonio Russo and Daniele Santini and Francesco Perrone and Giuseppe Tonini",
year = "2015",
month = "7",
day = "31",
doi = "10.1371/journal.pone.0133488",
language = "English",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "7",

}

TY - JOUR

T1 - Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies

T2 - A literature-based meta-analysis

AU - Vincenzi, Bruno

AU - Di Maio, Massimo

AU - Silletta, Marianna

AU - D'Onofrio, Loretta

AU - Spoto, Chiara

AU - Piccirillo, Maria Carmela

AU - Daniele, Gennaro

AU - Comito, Francesca

AU - Maci, Eliana

AU - Bronte, Giuseppe

AU - Russo, Antonio

AU - Santini, Daniele

AU - Perrone, Francesco

AU - Tonini, Giuseppe

PY - 2015/7/31

Y1 - 2015/7/31

N2 - Background The European Association for the Study of the Liver (EASL) criteria and the modified Response Evaluation Criteria in Solid Tumors (mRECIST) are currently adopted to evaluate radiological response in patients affected by HCC and treated with loco-regional procedures. Several studies explored the validity of these measurements in predicting survival but definitive data are still lacking. Aim To conduct a systematic review of studies exploring mRECIST and EASL criteria usefulness in predictive radiological response in HCC undergoing loco-regional therapies and their validity in predicting survival. Methods A comprehensive search of the literature was performed in electronic databases EMBASE, MEDLINE, COCHRANE LIBRARY, ASCO conferences and EASL conferences up to June 10, 2014. Our overall search strategy included terms for HCC, mRECIST, and EASL. Locoregional procedures included transarterial embolization (TAE), transarterial chemoembolization (TACE) and cryoablation. Inter-method agreement between EASL and mRECIST was assessed using the k coefficient. For each criteria, overall survival was described in responders vs. non-responders patients, considering all target lesions response. Results Among 18 initially found publications, 7 reports including 1357 patients were considered eligible. All studies were published as full-text articles. Proportion of responders according to mRECIST and EASL criteria was 62.4% and 61.3%, respectively. In the pooled population, 1286 agreements were observed between the two methods (kappa statistics 0.928, 95% confidence interval 0.912-0.944). HR for overall survival (responders versus non responders) according to mRECIST and EASL was 0.39 (95% confidence interval 0.26-0.61, p

AB - Background The European Association for the Study of the Liver (EASL) criteria and the modified Response Evaluation Criteria in Solid Tumors (mRECIST) are currently adopted to evaluate radiological response in patients affected by HCC and treated with loco-regional procedures. Several studies explored the validity of these measurements in predicting survival but definitive data are still lacking. Aim To conduct a systematic review of studies exploring mRECIST and EASL criteria usefulness in predictive radiological response in HCC undergoing loco-regional therapies and their validity in predicting survival. Methods A comprehensive search of the literature was performed in electronic databases EMBASE, MEDLINE, COCHRANE LIBRARY, ASCO conferences and EASL conferences up to June 10, 2014. Our overall search strategy included terms for HCC, mRECIST, and EASL. Locoregional procedures included transarterial embolization (TAE), transarterial chemoembolization (TACE) and cryoablation. Inter-method agreement between EASL and mRECIST was assessed using the k coefficient. For each criteria, overall survival was described in responders vs. non-responders patients, considering all target lesions response. Results Among 18 initially found publications, 7 reports including 1357 patients were considered eligible. All studies were published as full-text articles. Proportion of responders according to mRECIST and EASL criteria was 62.4% and 61.3%, respectively. In the pooled population, 1286 agreements were observed between the two methods (kappa statistics 0.928, 95% confidence interval 0.912-0.944). HR for overall survival (responders versus non responders) according to mRECIST and EASL was 0.39 (95% confidence interval 0.26-0.61, p

UR - http://www.scopus.com/inward/record.url?scp=84942133453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942133453&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0133488

DO - 10.1371/journal.pone.0133488

M3 - Article

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 7

M1 - e0133488

ER -